DRUG TESTING TRENDS

• What Your Policy May Not Cover!

Dru	ıg Arrests				
	Alaska				
		2010	2011	2012	
	Alcohol	363	392	284	
	Marijuana	1040	1211	817	
	Methamphetamine	185	194	182	
	Cocaine	145	108	74	
	Heroin	82	118	146	
				ļ	PAML
					ethelas sablaaktiness enterion is not to be copied or distribute t the specific permission of PAML LLC

Alaska				_
	2010	2011	2012	
Hydrocodone	627	1051	141	
Oxycodone	5,958	1,836	609	
All other prescriptions	2,668	2,548	2,839	
in dosage units				



Alaska's Statistics

Trust for America's Health, October 7,

Alaska has the 29th highest drug overdose mortality rate in the United States, with 11.6 per 100,000 people suffering drug overdose fatalities, according to a new report, *Prescription Drug Abuse: Strategies to Stop the Epidemic.*

Alaska has the highest Illicit Drug Use Rate in the Nation, according to a new Report based on SAMHSA's National Survey on Drug Use and Health (NSDUH).

Standard Drug Testing Panels Amphetamine/Methamphetamine Cocaine Barbiturates Benzodiazepines Methadone Methaqualone Opiates (Codeine/Morphine) Propoxyphene Phencyclidine (PCP) Cannabinoids (THC) Heroin Alcohol Oxycodone Experimentation of the state of th

Extended Panels Tramadol Fentanyl Meperidine Carisoprodol/Meprobamate ETG/ETS Nicotine Buprenorphine Synthetic Cannabinoids Bath Salts Vientee Cannabinoids

Designer Drugs

Designer Drugs are Legal Synthetic Alternatives to Illicit Drugs

Taken to:

Avoid detection of drug use in routine drug testsExperiment with a new drug

Designer Drugs Potential Dangers: Potency & dose are unknown Acute & chronic toxicity are unknown Presence of toxic contaminants are unknown

PAML

Designer Drugs

European Monitoring Center for Drugs & Drug Addiction (EMCDDA) identified more than 200 new designer drugs

Coming our way!

PAML

Designer Drugs US Legislation: Dec 8, 2011: Synthetic Drug Control Act 2011 July 9, 2012: Synthetic Drug Abuse Prevention Act July 2012: CP 47,497, CP 47,497-C8, JWH-018, JWH-019, JWH





Synthetic Cannabinoids WH-018, JWH-018 5/6-hydroxyindoles, JWH-018, hydroxypentyl, JWH-018 N-pertanoi: WH-019, WH-018 5/6-hydroxyindole, JWH-019, WH-018 5/6-hydroxyindole, WH-019, WH-019, WH-018 N-butanoi. WH-20, WH-018 5/6-hydroxyindole, JWH-20, WH-018 5/6-hydroxyindole, WH-20, WH-018 5/6-hydroxyindole, WH-20, WH-018 5/6-hydroxyindole, WH-20, WH-019, WH-018 S/6-hydroxypentyl, WH-20, WH-120 N-hydroxypentyl, WH-210 5-hydroxyindole, JWH-210 N-hydroxypentyl, WH-210 5-hydroxyindole, JWH-210 N-hydroxypentyl, WH-210, WH-210 S, RC5-8, HU-210 AKB-48, JUR-11, UR-144, LW-144

Synthetic Cannabinoids

Challenges

- · Large amount of analytes
- Constant change of what is in the market
- Lack of information about human urinary metabolites
- Higher potency producing lower metabolite concentrations
- Common metabolites for different analytes

















Synthetic Cannabinoids

 $\underline{\text{Efficacy}}$ is the maximum biological effect a drug can have based on its receptor binding.

<u>Potency</u> is a measure of the amount of drug needed to achieve a predefined biological effect.



Compound CB; Kj CB:XI/CB:XI Compound CB: Kj CB:XI/CB:XI JWH-18 9.0 0.32 XIR-11 24 0.09 JWH-019 9.8 0.57 UR-14 29 0.01 JWH-205 11 3.00 THC 41 0.88 JWH-210 .061 1.5 JWH-208 179 3.18 AM-411 6.9 7.50 JWH-201 1064 0.42 JWH-302 17 5.24 JWH-207 1598 2.33	ynthetic	Canr	nabin	oids			
JWH-18 9.0 0.32 XLR-11 24 0.01 JWH-19 9.8 0.57 XLR-14 29 0.01 JWH-219 9.8 0.57 XLR-13 24 0.03 JWH-250 11 3.00 THC 41 0.88 JWH-210 .061 1.5 JWH-208 179 3.18 AM-411 6.9 7.50 JWH-313 422 0.86 JWH-073 8.9 4.27 JWH-201 1064 0.42 JWH-302 17 5.24 JWH-207 1598 2.33							
JWH-18 9.0 0.32 XLR-11 24 0.01 JWH-19 9.8 0.57 XLR-14 29 0.01 JWH-219 9.8 0.57 XLR-13 24 0.03 JWH-250 11 3.00 THC 41 0.88 JWH-210 .061 1.5 JWH-208 179 3.18 AM-411 6.9 7.50 JWH-313 422 0.86 JWH-073 8.9 4.27 JWH-201 1064 0.42 JWH-302 17 5.24 JWH-207 1598 2.33							
JWH-019 9.8 0.57 UR-144 29 0.01 JWH-250 11 3.00 THC 41 0.88 JWH-210 .061 1.5 JWH-208 179 3.18 AM-411 6.9 7.50 JWH-313 422 0.86 JWH-302 17 5.24 JWH-207 1598 2.33	Compound	CB1 Ki	CB2Ki/CB1Ki	Compound	CB1 Ki	CB2Ki/CB1Ki	
JWH-250 11 3.00 THC 41 0.88 JWH-210 .061 1.5 JWH-208 179 3.18 AM-411 6.9 7.50 JWH-313 422 0.86 JWH-073 8.9 4.27 JWH-201 1064 0.42 JWH-302 17 5.24 JWH-207 1598 2.33 CB+Ki – the lower the number the more tightly it binds to receptor Image: State	JWH-18	9.0	0.32	XLR-11	24	0.09	
JWH-210 .061 1.5 JWH-208 179 3.18 AM-411 6.9 7.50 JWH-313 422 0.86 JWH-073 8.9 4.27 JWH-201 1064 0.42 JWH-302 17 5.24 JWH-207 1598 2.33 CB+Ki - the lower the number the more tightly it binds to receptor Interval Interval Interval	JWH-019	9.8	0.57	UR-144	29	0.01	
AM-411 6.9 7.50 JWH-313 422 0.86 JWH-073 8.9 4.27 JWH-201 1064 0.42 JWH-302 17 5.24 JWH-207 1598 2.33 CB1Ki – the lower the number the more tightly it binds to receptor	JWH-250	11	3.00	THC	41	0.88	
JWH-073 8.9 4.27 JWH-201 1064 0.42 JWH-302 17 5.24 JWH-207 1598 2.33 CB:Ki – the lower the number the more tightly it binds to receptor	JWH-210	.061	1.5	JWH-208	179	3.18	
JWH-302 17 5.24 JWH-207 1598 2.33 CB1Ki - the lower the number the more tightly it binds to receptor	AM-411	6.9	7.50	JWH-313	422	0.86	
CBrKi – the lower the number the more tightly it binds to receptor	JWH-073	8.9	4.27	JWH-201	1064	0.42	
, , , , , , , , , , , , , , , , , , ,	JWH-302	17	5.24	JWH-207	1598	2.33	
PAN							
						ļ	PAM







Bath Salts

The Drug That Never Lets Go - PBS NewsHour

'Bath Salts' A Deadly New Drug With A Deceptively Innocent Name - Forbes

"It Felt So Evil" - Former Bath-Salts Addict

PAML

Bath Salts
We didn't ask, 'Are you seeing monsters and aliens?' They were telling us that.

Bath Salts	
Negative Side Effects:	
Racing Heart	Paranoia
High Blood Pressure	Hallucinations
Chest Pains	Panic Attacks
Serious Side Effects:	
Dehydration	Breakdown of Skeletal Muscle Tissue
Kidney Failure	





























































Opiates			
Drug	Duration	Half-Life	Threshold
Fentanyl	1 – 2 hrs	1.5 – 6 hrs	50ug/hr
Meperidine	2 – 4 hrs	3 – 4 hrs	NA
Oxycodone	4 – 6 hrs	3 – 4.5 hrs	80 mg/24hrs
Oxymorphone	3 – 6 hrs	7 – 9 hrs	40 mg/24hrs
Hydrocodone	4 – 8 hrs	3.3 – 4.5 hrs	120 mg/24hrs
Hydromorphone	4 – 5 hrs	2 – 3 hrs	30 mg/24hrs
Codeine	4 – 6 hrs	3 hrs	800 mg/24hrs
Morphine	3 – 6 hrs	1.5 – 3 hrs	120 mg/24hrs
Methadone	4 – 6 hrs	15 – 30 hrs	40 mg/24hrs
Levorphanol	6 – 8 hrs	12 – 16 hrs	
Propoxyphene	4 – 6 hrs	6 – 12 hrs	NA
			The presentation at a constrained or at a cons



Opiates

Factors influence drug metabolism:

Smoking – Cigarette smokers metabolize some drugs more rapidly than nonsmokers because of enzyme induction.
 Pesticides – Industrial workers exposed to some pesticides metabolize certain drugs more rapidly than unexposed individuals.
 Diet – charcoal broiled foods and cruciferous vegetables are known to induce CYP1A enzymes, whereas grapefruit juice is known to inhibit the CYP3A metabolism of co-administered drug substrates.
 Age – influences absorption, distribution, and elimination.
 Sex – Clinical reports suggest that similar sex-dependent differences in drug metabolism exist for ethanol, propranolol, some benzodiazepines, estrogens, and salcylates.
 Drug-Drug Interactions – Depending on the residual drug levels at the active site, they also may competitively inhibit metabolism of a simultaneously administered drug.

Opiate	5			
CYP1A2	CYP2C9	CYP2D6	СҮРЗА	4
Amitriptyline	Celecoxib	Amitriptyline	Amitriptyline	-
Desipramine	Ibuprofen	Bupropion	Bupropion	
Imipramine	Phenytoin	Codeine	Citalopram	
Lidocaine	Topiramate	Desipramine	Dextromethorphan	
Nortriptyline		Dextromethorphan	Fentanyl	
Phenytoin	Inhibitors	Doxepin	Fluoxetine	
	Fluoxine	Fluoxetine	Imipramine	
Inhibitors		Hydrocodone	Ketamine	
Citalopram	Inducers	Oxycodone	Methadone	
Fluoxetine	Carbamazepine	Tramadol	Venlafaxine	
Mexiletine	Fluoxetine	Methadone	Benzodiazepines	
			Buprenorphine	
Inducers Carbamazepine		Inhibitors Desipramine	Inhibitors	Inducers
Phenytoin		Fluoxetine	Ervthromycin	Carbamazepine
Smoking		Haloperidol	Eluoxetine	Dexamethasone
		Sertraline	Grapefruit	Phenytoin
			Sertraline	
		Inducers	Ketoconazole	
		Carbamazepine	Clarithromycin	















